Lansoprazole Capsule, Delayed Release
Product Images NDC 68071-3585

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 68071-3585). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 3585 3)

Pdp (68071 3585 3)
Label for Lansoprazole 30 mg delayed-release capsules from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 30 capsules with instruction to see the manufacturer's label for full ingredients. It includes barcodes, lot number, expiration date fields, warnings to keep out of reach of children, and storage instructions at controlled temperatures.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph showing the mean severity of day heartburn over time for evaluable patients receiving placebo, lansoprazole 15 mg QD, or lansoprazole 30 mg QD. The x-axis represents days from the start of treatment, from -5 to 60, and the y-axis represents mean severity of day heartburn on a scale from 0 (none) to 3 (severe). Both lansoprazole 15 mg and 30 mg treatments show a decrease in heartburn severity compared to placebo over time.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the mean severity of night heartburn over time for evaluable patients, comparing placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily. The x-axis represents days from start of treatment, and the y-axis indicates mean severity of night heartburn on a scale from 0 (none) to 3 (severe). Lansoprazole groups show lower severity compared to placebo over the treatment period.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of lansoprazole, showing its molecular framework with a sulfoxide group linking two aromatic rings, one containing a benzimidazole and the other a substituted pyridine ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.